Share your requirements to help us to customize the report.
   I acknowledge that I have read the Privacy Policy
Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • FAQs

    Global Point of Care Diagnostics Market size was valued at USD 47.4 Billion in 2024 and is poised to grow from USD 50.01 Billion in 2025 to USD 76.75 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026–2033).

    Point of care diagnostics providers should focus on increasing the efficacy of their tests and reduce their result times by investing in R&D. Developing at-home and rapid POC test kits is also a prominent opportunity for companies as per this global point of care diagnostics market analysis. Targeting countries with developed healthcare infrastructure is also a key strategy for all market players. 'Abbott Laboratories (US)', 'Siemens Healthineers AG (Germany)', 'Quidel Corporation (US)', 'F. Hoffman-La Roche Ltd. (Switzerland)', 'Danaher Corporation (US)', 'Becton, Dickinson and Company (US)', 'Chembio Diagnostics (US)', 'EKF Diagnostics (UK)', 'Trinity Biotech plc (Ireland)', 'Instrumentation Laboratory (US)', 'PTS Diagnostics (US)', 'Sekisui Diagnostics (US)'

    Advanced technologies such as microfluidics, lab‑on‑a‑chip platforms, biosensors, and AI have made point of care diagnostics solutions more compact and accurate. High‑performance multiplex assays enable simultaneous detection of multiple biomarkers from a single sample, enhancing efficiency. Such advancements help simplify workflows, reduce user error, and extend point of care diagnostics applicability across clinical and non‑clinical environments.

    Expansion of Molecular POC Testing: Advancements in molecular diagnostics technologies have brought them out of the confines of laboratories to point of care settings. Rapid molecular assays for infectious diseases such as COVID-19, influenza, and STDs offer high accuracy and fast turnaround times, improving outbreak containment and targeted treatment. Platforms using isothermal amplification or CRISPR-based detection are gaining traction due to their simplicity and portability. The growing demand for quick, accurate diagnostics is expected to make this an indispensable point of the care diagnostics industry trend in the long run.

    Why is Adoption of Point of Care Diagnostics High in North America?

    Feedback From Our Clients

    Global Point of Care Diagnostics Market

    Report ID: SQMIG35D2329

    $5,300
    BUY NOW GET FREE SAMPLE